Menu hamburgerclose

Advancing Peritoneal Dialysis (PD)

Millions of patients worldwide depend on dialysis to survive. Our novel fluid, PDprotec®, is designed to improve the outcomes of this treatment and reduce the burden of kidney failure for patients and health care providers.
PDprotec® addresses the global market for
PD-fluids (USD 3 billion) and has the potential to increase the share of PD in the overall dialysis market (USD 13 billion)

> more information

PDprotec®key advantages

Improved clinical outcome

Prolonged time for which patients can benefit from PD

Increase market share of PD in dialysis overall

The Zytoprotec success story

Beginning of
Phase III

> read more

  • Product prepared to enter pivotal Phase III trial in 2021
  • Outstanding safety and efficacy demonstrated for PDprotec® in Phase I/II and Phase II studies
  • Orphan Drug designation granted by FDA
  • Follow-on PD fluid ICOprotec™ ready for clinical development

PDprotec® NEWS

Zytoprotec Phase II Peritoneal Dialysis Study: Last Patient Out

Vienna, Europe, November 14, 2016 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids with cytoprotective properties, announced today that the last patient has completed treatment in a Phase II study with its lead product, PDprotec®. The Company expects results of this trial to be available in the first quarter of 2017.

> read more

Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study

Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.

> read more

FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid

Vienna, Europe, December 14, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec®, the Company's peritoneal dialysis fluid for the treatment of patients with end-stage renal disease (kidney failure).

> read more

> show all

Award-winning science
and world-class
clinical research

To improve the lives of patients.

Science and Technology

The development of PDprotec® has been advanced by Zytoprotec’s own scientists and clinical experts and by the expertise and support provided by global leaders in the field of PD represented in our Scientific Advisory Board.

Scientific Advisory Board

A clear step forward in next generation PD solutions.
Prof. Dr. Nicholas Topley

They say a bit of stress is good for you – Zytoprotec research shows nicely how you can incorporate this principle into clinical practice of PD.
Prof. Dr. Janusz Witowski

An attractive approach to preserve the peritoneal membrane.
Prof. Dr. Manuel Lopez Cabrera